Yandex Nv A (YNDX) Shareholder Capital International Boosted Position by $419,200 as Stock Price Rose; Bb Biotech Ag Holds Holding in Regeneron Pharmaceuticals (REGN)

February 23, 2018 - By Adrian Erickson

Bb Biotech Ag increased its stake in Regeneron Pharmaceuticals Inc. (REGN) by 13.89% based on its latest 2017Q3 regulatory filing with the SEC. Bb Biotech Ag bought 25,000 shares as the company’s stock rose 21.24% with the market. The institutional investor held 205,000 shares of the health care company at the end of 2017Q3, valued at $91.66 million, up from 180,000 at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Regeneron Pharmaceuticals Inc. for a number of months, seems to be bullish on the $33.98 billion market cap company. The stock decreased 0.53% or $1.69 during the last trading session, reaching $315.82. About 841,559 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since February 23, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Capital International Inc increased its stake in Yandex Nv A (YNDX) by 4.13% based on its latest 2017Q3 regulatory filing with the SEC. Capital International Inc bought 13,100 shares as the company’s stock rose 15.61% with the market. The institutional investor held 329,925 shares of the programming company at the end of 2017Q3, valued at $10.87 million, up from 316,825 at the end of the previous reported quarter. Capital International Inc who had been investing in Yandex Nv A for a number of months, seems to be bullish on the $13.83B market cap company. The stock decreased 2.53% or $1.1 during the last trading session, reaching $42.39. About 3.55M shares traded or 38.91% up from the average. Yandex N.V. (NASDAQ:YNDX) has risen 50.13% since February 23, 2017 and is uptrending. It has outperformed by 33.43% the S&P500.

Among 9 analysts covering Yandex N.V. (NASDAQ:YNDX), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Yandex N.V. had 21 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Monday, March 14. The firm has “Buy” rating given on Wednesday, October 25 by Deutsche Bank. On Friday, July 14 the stock rating was maintained by Deutsche Bank with “Buy”. The company was maintained on Tuesday, January 16 by Deutsche Bank. The company was initiated on Monday, July 18 by HSBC. The firm has “Hold” rating given on Tuesday, August 4 by Zacks. The stock of Yandex N.V. (NASDAQ:YNDX) earned “Overweight” rating by Morgan Stanley on Tuesday, November 17. The stock has “Neutral” rating by Citigroup on Friday, May 6. The firm earned “Neutral” rating on Wednesday, September 16 by Goldman Sachs. On Friday, July 31 the stock rating was maintained by Deutsche Bank with “Buy”.

Capital International Inc, which manages about $18.21 billion and $683.96 million US Long portfolio, decreased its stake in Goldman Sachs Group Inc (NYSE:GS) by 4,100 shares to 4,735 shares, valued at $1.12 million in 2017Q3, according to the filing. It also reduced its holding in Occidental Petroleum Corp (NYSE:OXY) by 8,200 shares in the quarter, leaving it with 22,450 shares, and cut its stake in Amazon.Com Inc (NASDAQ:AMZN).

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 19 Hold. Therefore 39% are positive. Regeneron Pharmaceuticals Inc. had 118 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Hold” rating by Canaccord Genuity on Wednesday, January 27. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, August 5. Leerink Swann maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Monday, April 4 with “Outperform” rating. BMO Capital Markets maintained it with “Hold” rating and $491.0 target in Monday, September 11 report. The firm earned “Neutral” rating on Thursday, February 16 by Goldman Sachs. The firm has “Buy” rating by Credit Suisse given on Thursday, August 3. The company was upgraded on Monday, December 12 by Chardan Capital Markets. The firm has “Hold” rating by BMO Capital Markets given on Monday, October 16. The firm has “Buy” rating by Piper Jaffray given on Thursday, September 7. The stock has “Buy” rating by BTIG Research on Friday, June 30.

Since August 25, 2017, it had 0 insider purchases, and 5 sales for $2.48 million activity. GOLDSTEIN JOSEPH L had sold 1,000 shares worth $325,600. $712,500 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by BROWN MICHAEL S on Thursday, October 5. Landry Robert E had sold 427 shares worth $210,693 on Wednesday, August 30. Sanofi bought $34.84 million worth of stock.

Bb Biotech Ag, which manages about $3.61B US Long portfolio, decreased its stake in Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 110,000 shares to 1.11 million shares, valued at $130.57M in 2017Q3, according to the filing.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.21, from 1.38 in 2017Q2. It worsened, as 56 investors sold REGN shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Boston Private Wealth Lc stated it has 907 shares. Eventide Asset Ltd Liability holds 0.19% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 7,500 shares. Baystate Wealth Mgmt Limited Com holds 7 shares or 0% of its portfolio. Kelly Lawrence W & Assoc Incorporated Ca reported 25,265 shares. Loring Wolcott & Coolidge Fiduciary Advsr Llp Ma holds 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 745 shares. Alliancebernstein Ltd Partnership holds 219,821 shares or 0.07% of its portfolio. Savings Bank Of Montreal Can holds 0.02% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 42,681 shares. Main Street Research Limited Liability Corporation stated it has 725 shares. Exxonmobil Mngmt Inc Tx has 0.16% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 14,030 shares. Harding Loevner Ltd Partnership accumulated 3.66M shares. Citigroup owns 0.02% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 61,676 shares. Sei Invests Company holds 0.29% or 184,637 shares. Premier Asset Limited Liability Company reported 3.26% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Pictet Asset Mgmt stated it has 327,899 shares. 74,885 were accumulated by Nationwide Fund Advsr.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>